Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5602116 | SANOFI | Method for treating and preventing secondary hyperparathyroidism |
Feb, 2014
(10 years ago) | |
US6903083 | SANOFI | Stabilized hydroxyvitamin D |
Jul, 2021
(2 years ago) | |
US7148211 | SANOFI | Formulation for lipophilic agents |
Sep, 2023
(7 months ago) |
Hectorol is owned by Sanofi.
Hectorol contains Doxercalciferol.
Hectorol has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Hectorol are:
Hectorol was authorised for market use on 06 April, 2000.
Hectorol is available in capsule;oral, injectable;injection dosage forms.
Hectorol can be used as reduction of elevated ipth levels in the mgt of secondary hyperparathyroidism in patients undergong chronic renal dialysis.
The generics of Hectorol are possible to be released after 14 September, 2023.
Drugs and Companies using DOXERCALCIFEROL ingredient
Market Authorisation Date: 06 April, 2000
Treatment: Reduction of elevated ipth levels in the mgt of secondary hyperparathyroidism in patients undergong chronic renal dialysis
Dosage: INJECTABLE;INJECTION; CAPSULE;ORAL